Company Active LTD

Company profile

Mirada Medical Limited

Software solutions for AI autocontouring | Mirada | Cancer Care Software

Mirada provide medical imaging and software solutions for AI autocontouring. We help healthcare professionals to accelerate cancer care.

CRN
06515901
Founded
2008
Age
18

Overview

Legal name
MIRADA MEDICAL LIMITED
Region
South East England
Registered address
NEW BARCLAY HOUSE
234 BOTLEY ROAD
OXFORD
OXFORDSHIRE
ENGLAND
OX2 0HP
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

10 events
27 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

13 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

27 Oct
2024

Accounts With Accounts Type Audit Exemption Subsiduary

Accounts PDF pending

AA | Transaction MzQ0MTA0OTkyMGFkaXF6a2N4 | Paper/PDF filed

Published 30 Oct 2024 07:31

27 Oct
2024

Legacy

Other

GUARANTEE2 | Transaction MzQ0MTA0OTg3NWFkaXF6a2N4 | Paper/PDF filed

Published 30 Oct 2024 07:17

27 Oct
2024

Legacy

Other

AGREEMENT2 | Transaction MzQ0MTA0OTg4OGFkaXF6a2N4 | Paper/PDF filed

Published 30 Oct 2024 07:17

27 Oct
2024

Legacy

Accounts PDF pending

PARENT_ACC | Transaction MzQ0MTA0OTg5NWFkaXF6a2N4 | Paper/PDF filed

Published 30 Oct 2024 07:06

02 Oct
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzODE1OTU4OGFkaXF6a2N4

Published 02 Oct 2024 03:30

27 Feb
2008

Incorporated

Inception

Company registered at Companies House

Public funding

14 awards
First funded
2011
Funded years
2011, 2012, 2014, 2015, 2017, 2018, 2019, 2020, 2021, 2024
Age at first award
3 years

Projects

2024 Collaborative R&D Lead participant

End-to end AI-assisted workflow for PSMA PET/CT reporting

1 Mar 2024 to 31 Mar 2026

Awarded
£335,211
Total cost £558,685

Prostate specific membrane antigen (PSMA)-targeted imaging agents are a relatively new family of radiotracers used for imaging prostate cancer patients with Positron Emission Tomography (PET) for diagnostics, therapy selection and response assessment and a major growth area in clinical practice. Whilst PSMA PET/CT offers high sensitivity in detecting meta...

2021 Collaborative R&D Lead participant

Outlines to outcomes : Second-generation AI auto-contouring for radiotherapy

12 Apr 2021 to 12 Jul 2022

Awarded
£583,402
Total cost £583,402

External Beam Radiotherapy (RT) is a cornerstone of modern cancer treatment and is offered to 50% of cancer patients in the UK. RT planning involves manually outlining the target to be irradiated and healthy tissues and organs to be avoided on medical images of the patient (such as CT scans). This planning is time-consuming and skill-intensive, and there ...

2020 Feasibility Studies Lead participant

Automation in Radiotherapy Workflow

1 Jun 2020 to 30 Nov 2020

Awarded
£105,488
Total cost £206,536
2020 EU-Funded Lead participant

Automation in Radiotherapy Workflow

1 Jan 2020 to 30 Jun 2022

Awarded
£309,801
Total cost £516,335

Awaiting Public Project Summary

2019 Collaborative R&D Lead participant

Integrated AI-enabled platform for adaptive radiotherapy dose planning

1 Jul 2019 to 30 Apr 2021

Awarded
£386,733
Total cost £773,466

"External Beam Radiotherapy (RT) is a cornerstone of modern cancer treatment, utilized on its own or in combination with surgery and/or chemotherapy. During RT, high energy radiation, generated within a linear accelerator, is directed at a tumour, thereby destroying it, but also inevitably irradiating nearby healthy tissue. It is therefore necessary to ca...

2019 CR&D Bilateral Lead participant

Determining the value proposition for DLCExpert in NHS radiotherapy planning

1 Apr 2019 to 30 Sep 2019

Awarded
£24,724
Total cost £49,448

"For approximately 50% patients diagnosed with cancer, radiotherapy can be offered as a treatment instead of (or sometimes in combination with) surgery or chemotherapy. Radiotherapy directs beams of radiation to specific regions of the body to kill the cancer cells. Contouring is a critical part of radiotherapy treatment planning which defines where the r...

2019 Collaborative R&D

London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare

1 Feb 2019 to 31 Mar 2023

Awarded
£134,525
Total cost £224,208

"The London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will improve NHS patient care and health outcomes, reduce healthcare costs and support the growth of companies, supporting the economy. It will do this by applying artificial intelligence technologies to medical imaging (for example MRI scans, CT scans PET scans and ul...

2019 Collaborative R&D Lead participant

Dosimetry for molecular radiotherapy treatment planning (Stage 1 - no 23440)

1 Jan 2019 to 30 Apr 2019

Awarded
£32,282
Total cost £32,282

"Molecular radiotherapy (MRT) is a treatment modality for cancer. It involves the administration of radioactive atoms with the aim of locally irradiating tumours. Dosimetry is concerned with the measurement of the absorbed radiation dose to each disease site. Many of the treatments in MRT are currently prescribed empirically or with a fixed quantity of ra...

2019 Collaborative R&D

National Consortium of Intelligent Medical Imaging (NCIMI)

1 Jan 2019 to 31 Mar 2023

Awarded
£0
Total cost £211,912

"We have formed a consortium of collaborating hospitals and commercial companies with public and patient involvement and input from charities to enable us to work with the public and the NHS to best develop and test the use of Artificial Intelligence programmes to improve health care. We are working with university academics and NHS hospitals across the c...

2018 Feasibility Studies Lead participant

Improving quality assurance in radiotherapy

1 Mar 2018 to 31 Oct 2018

Awarded
£34,781
Total cost £49,688

"Radiotherapy is a key method for treating cancer in which high energy radiation is directed at a tumour to destroy it by disrupting DNA replication. However, it is inevitable that surrounding healthy tissue is also irradiated during the process. It is therefore necessary to plan any therapy so as to maximise the tumour's received dose while minimising th...

2017 Feasibility Studies Lead participant

Commercial Feasibility of Deep Learning based Medical Image Registration

1 Aug 2017 to 31 Oct 2018

Awarded
£56,535
Total cost £94,587

Various methods of imaging are used within medicine to provide different information for the diagnosis and treatment of various diseases. Image Registration is a valuable tool that establishes an alignment of images to one another and, as a result, permits meaningful comparison and visualisation of multiple images. For example, a patient’s response to tre...

2015 EU-Funded Lead participant

Eurostars Cloud-Atlas

1 May 2015 to 31 Oct 2017

Awarded
£287,889
Total cost £479,816

Awaiting Public Project Summary

Product types

Collaborative R&D CR&D Bilateral EU-Funded Feasibility Studies GRD Proof of Concept